Loading clinical trials...
Loading clinical trials...
Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms
Conditions
Interventions
Iodine I 131 MOAB 8H9
Iodine I 131 MOAB 8H9
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
February 5, 2004
Primary Completion Date
February 2, 2022
Completion Date
February 2, 2022
Last Updated
December 26, 2023
NCT06926283
NCT07548177
NCT03050268
NCT06422806
NCT07467772
NCT05969860
Lead Sponsor
Y-mAbs Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions